SB1838, titled the DeOndra Dixon INCLUDE Project Act of 2025, would amend the Public Health Service Act to formally authorize a National Institutes of Health research, training, and investigation program focused on Down syndrome. The bill directs the Secretary of Health and Human Services, acting through the NIH Director, to carry out the INCLUDE Project in consultation with other federal agencies and partners. Its stated purpose is to expand scientific understanding of Down syndrome across the lifespan and improve health outcomes for individuals with Down syndrome and their families.
The bill lays out a broad research agenda. It includes basic science on chromosome 21, building and maintaining a large study population, expanding clinical trials that include or are specifically designed for people with Down syndrome, studying biological mechanisms behind co-occurring conditions, identifying biomarkers for diagnosis and treatment, examining why conditions such as Alzheimer’s disease and autoimmunity are common in this population, and improving quality of life. It also requires coordination across NIH institutes and centers to avoid duplicative research, provides for technical assistance to grantees, and mandates biennial reports to Congress describing funded or conducted research and any real-world evidence relevant to clinical care.
In terms of state and federal law, the bill would amend the federal Public Health Service Act by adding a new section on Down syndrome research. It would not directly change state statutes, but it could influence medical research priorities, federal grantmaking, and clinical research infrastructure nationwide. The bill would also likely affect NIH programs, universities, hospitals, researchers, and patient advocacy organizations involved in Down syndrome studies.
The overall sentiment reflected in the bill text and sponsorship is strongly supportive and affirmative. The findings emphasize the prevalence of Down syndrome, the increased life expectancy of people with the condition, and the value of research that supports independence, health, and participation in society. The bipartisan and bicameral sponsorship also suggests broad interest in the measure, though no committee transcript or vote data is available here to show debate or opposition.
No specific points of contention are documented in the available materials. Potential areas of policy interest, based on the bill’s structure, could include whether NIH should prioritize this research area over others, how to avoid duplicating existing studies, and how broadly clinical trials should be designed to include individuals with Down syndrome. However, the provided record does not show any formal objections or amendments.
The bill would add a new federal research authorization within the Public Health Service Act for a Down syndrome-focused NIH program, requiring coordinated research, training, and investigation and regular reporting to Congress. It would shape federal biomedical research priorities and funding, but it would not directly alter state law. Affected parties would include NIH, other federal health agencies, researchers, clinical trial sponsors, and individuals with Down syndrome and their families.
The available record indicates a positive, bipartisan posture toward the bill. It was introduced by senators from both parties and is framed around improving health outcomes, expanding research, and supporting people with Down syndrome across the lifespan. No votes or committee debate are provided, so there is no evidence of organized opposition in the record supplied.
No explicit contention appears in the provided materials because there are no committee transcripts or recorded votes. If concerns were raised, they would likely center on research prioritization, duplication of existing NIH efforts, implementation costs, or how to structure inclusive clinical trials, but these issues are not documented in the record here.